OpenLobby.EU
Explore

Access VetMed

Our mission is to increase ACCESS – availability, compliance, convenience, efficacy, safety, and savings – of veterinary medicines to veterinarians, and farm and companion animal owners in Europe.

Lobbying Activity

Meeting with Eva Maria Zamora Escribano (Head of Unit Health and Food Safety)

27 Jan 2026 · Veterinary Medicinal Products: - Follow up to the stakeholders meeting of October 2025 - Access VetMed Manifesto - Pharmacovigilance

Meeting with Eva Maria Zamora Escribano (Head of Unit Health and Food Safety) and AnimalhealthEurope

29 Oct 2025 · First of regular meetings with stakeholders. - Supporting innovation - Optimising the application of Regulation (EU) 2019/6 - Fighting antimicrobial resistance

Response to Critical Medicines Act

4 Jul 2025

Access VetMed, representing the industry of generic and added-value veterinary medicines in Europe, welcomes the European Commissions initiative to establish a Critical Medicines Act and appreciates the opportunity to contribute to this important consultation. We strongly support the efforts to enhance the availability and resilience of medicines supply in the European Union. It is crucial that the Critical Medicines Act recognises the vital role of veterinary medicinal products (VMPs) in ensuring public health, safeguarding animal welfare, and securing food production across the EU. Veterinary medicines, many of which are included in the Union List of Critical Medicines, are essential for the prevention and treatment of animal diseases. Their continued availability is indispensable not only for animal health, but also for the protection of human healthparticularly in the context of zoonotic diseasesand for maintaining a stable and safe food supply chain across the EU. The veterinary and human pharmaceutical sectors share many interdependencies, including common sources of active pharmaceutical ingredients (APIs), excipients, packaging components, and manufacturing facilities. To ensure the effectiveness of the Critical Medicines Act, these interdependencies must be fully acknowledged and addressed in its design and implementation. Failing to do so may result in unintended consequences for the availability of veterinary medicines. We therefore strongly encourage the Commission to ensure that the Critical Medicines Act - is fully aligned with the One Health approach, which recognises the interconnectedness of human, animal, and environmental health. - takes the animal health sector into consideration in any impact assessments, supply chain analyses, or strategic interventions - prevents unintended disruptions to the availability of VMPs by ensuring that actions targeting human medicines do not compromise veterinary supply chains.
Read full response

Response to Communication on the EU Stockpiling Strategy

9 May 2025

Access VetMed, representing the European industry of generic and added-value veterinary medicines, welcomes the European Commissions efforts to strengthen crisis preparedness through a coordinated EU stockpiling strategy. Our comments to this call for evidence are hereby attached.
Read full response

Meeting with Eva Maria Zamora Escribano (Head of Unit Health and Food Safety) and AnimalhealthEurope

31 Jan 2025 · Informative session on the development of the draft Implementing Regulations on good manufacturing practice for veterinary medicinal products and for active substances used as starting materials for veterinary medicinal products

Response to List of antimicrobials forbidden for cascade use in animals, or authorised for cascade use subject to certain conditions

20 Jun 2024

At Access VetMed we welcome the opportunity to provide feedback to this draft implementing regulation and support the proposal made by the European Commission. The proposal endorses the scientific and thorough assessment from the EMA, which also takes into account the views of ECDC, EFSA and CHMP, reflecting a solid scientific approach while in line with the EUs One Healths concept. The provisions in the implementing act are generally regarded as pragmatic and we appreciate that the proposed regulation attempts to increase the availability of therapeutic options for minor species. The restrictions proposed are supported. The impact of the restrictions on food producing animals may in fact be limited, since most of the EU Member States have already implemented similar provisions through national guidelines. In this regard, it monitoring the implementation of Article 107(7)1 regarding the allowance from Member States to restrict the use of certain antimicrobials based on national policies on prudent use will be a key aspect. From Access VetMed perspective, it would be advisable ensuring that enforcement at national level is harmonized and does not deviate from the EMA scientific advice. As a very minor comment (wording), we suggest the following correction in Annex: - modifying the conditions for amphotericin B, i.e. treatment of animals with leishmaniasis
Read full response

Response to Rules on appropriate measures to ensure effective and safe use of veterinary medicinal products for oral administration

10 Jan 2024

Access VetMed welcomes the opportunity to provide feedback to this initiative and supports the implementation of a legal framework which ensures a safe and efficient use of veterinary medicinal products administered orally via routes other than medicated feed, so that the needs for animal and public health in the Union are covered. Our comments are hereby attached.
Read full response

Response to Uniform rules on the size of small immediate packaging units for veterinary medicinal products

15 Dec 2023

Access VetMed is grateful for the opportunity to provide comments and welcomes the Commission proposal. We would only suggest one addition under Article 1, to expand the scope of types of immediate packaging to be considered to be small immediate packaging units - to add a foil blister/pouch, i.e. an additional layer of packaging often used for spot on pipettes or other types of applicators.
Read full response

Response to List of abbreviations and pictograms to be used on the labelling of veterinary medicinal products

15 Dec 2023

Access VetMed welcomes the opportunity to provide feedback to this draft implementing regulation on the list of abbreviations and pictograms to be used on the labeling and packaging of veterinary medicinal products. Our comments are enclosed in separate pdf file.
Read full response

Response to Ban on the use of certain antimicrobials in animals and products of animal origin imported to the Union

3 Jan 2023

Access VetMed welcomes the opportunity to provide feedback on the delegated regulation supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council on the application of the prohibition of use of certain antimicrobial medicinal products in animals or products of animal origin exported from third countries into the Union. Overall, we welcome this proposal which creates a level playing field for imports of products of animal origin into the EU, and aims at supporting Regulation (EU) 2019/6 in meeting its objective to contain the spread of antimicrobial resistance. Access VetMed has only one comment related to recital (8) on pages 4-5. The statement of concern is: In addition, there is increasing scientific evidence that the use of antimicrobials in food-producing animals has an impact on the development of antimicrobial resistance. This statement is too general and not substantiated. As it is written, it seems to suggest that the use of antimicrobials in food-producing animals is the main driver in the development of antimicrobial resistance, which is clearly not the case. While it may be true that, in some cases, the use of antimicrobials in food-producing animals can have an impact on the development of antimicrobial resistance, the statement is too broad and it would benefit from some modification. Access VetMed would like to propose this statement in replacement of the one in the draft delegated act: In addition, there is increasing scientific evidence that the use of antimicrobials in food-producing animals is a factor that can impact on the development of antimicrobial resistance in certain circumstances.
Read full response

Response to List of antimicrobials reserved for treatment of certain infections in humans

16 May 2022

Access VetMed welcomes the opportunity to provide feedback to this draft implementing regulation designating antimicrobials or groups of antimicrobials reserved for the treatment of certain infections in humans. Antimicrobial therapy is crucial to effectively combat and control infectious diseases in animals and humans. The continued availability of a wide range of effective antimicrobials in veterinary medicine is of vital importance not only to treat animal diseases but also to help maintaining public health and to prevent human disease, due to the fundamental role that animal health plays in the One Health triad. Access VetMed supports the implementing act proposed by the European Commission. In its Annex, the list of restricted antimicrobials endorses the scientific and thorough assessment from the EMA, which also takes into account reports from ECDC and EFSA, as well as the advice of international experts from WHO and OIE. Indeed, scientists from both human and veterinary medicines fields have made significant efforts to establish such a list, referencing the best and widest scientific knowledge currently available. We therefore welcome that science has prevailed over politics when establishing the list of restricted antimicrobials in veterinary medicine, while embracing the EU’s One Health concept as well. Access VetMed thanks the European Commission for addressing this important public health problem, in particular in the context of implementing the new regulation on veterinary medicines 2019/6. This regulation not only foresees the implementation of a list of antimicrobials reserved for human use, but presents a series of holistic measures for enhancing responsible use while making EU a best practice region. From our side, we will to continue taking all necessary measures to contribute actively and responsively to fight against antimicrobial resistance, which can only be achieved through science-based solutions and enforcement of prudent use of antimicrobials both in the human and veterinary medicines’ sectors.
Read full response

Response to Good distribution practices for VMPs

9 Jun 2021

EGGVP has reviewed and generally agrees with the provisions and requirements set up in the draft implementing act. In many Member States, national inspectors auditing VMPs wholesalers and distributors already adopt the requirements of the European Commission Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (or national GDPs) as the legal basis for the inspection. In this regard, EGGVP welcomes that such human medicines guidelines have been taken as the basis for recommendations. Today many businesses on the veterinary field implement these standards already, and therefore most sections of the draft implementing act could in principle be implemented without disproportionate effort by these companies. The only concern arises from the fact that not all EU Member States have adopted human GDPs for veterinary products. Therefore, for these businesses which are not up to standards, it would be appropriate to set up a transition period for implementation.
Read full response

Response to Good pharmacovigilance practice for veterinary medicines

8 Jun 2021

Please find EGGVP's feedback in attachment.
Read full response

Response to Details for the application dossier for the authorisation of a veterinary medicine

5 Dec 2020

EGGVP is grateful for the opportunity to provide comments on this draft delegated act. Our comments are enclosed. Please note these refer to the Annex only.
Read full response

Meeting with Anne Bucher (Director-General Health and Food Safety)

28 Mar 2019 · discussion on market on generic veterinary medicines; implementation of the veterinary medicine package